



ASX Announcement

BrainChip Announces Addition of Nobel Prize Laureate to Scientific Advisory Board (SAB)

Professor Barry J. Marshall to Join the BrainChip SAB

-
- Company Expands Scientific Advisor Board
 - Focus on Smart Health Expanded with Addition of Nobel Prize Winner
-

Sydney, NSW Australia – 23 July 2020 – [BrainChip Holdings Ltd](#) (ASX: BRN), a leading provider of ultra-low power, high performance AI technology today announced that Prof. Barry J. Marshall, a Nobel Prize laureate in Physiology and Medicine has joined the Company's Scientific Advisory Board. Prof. Marshall was awarded the Nobel Prize for Physiology or Medicine in 2005 for his pioneering work in the discovery of the bacterium *Helicobacter pylori* and its role in gastritis and peptic ulcer disease."

Prof. Marshall joins Prof. Adam Osseiran and Prof. Simon J. Thorpe on BrainChip's SAB. The SAB was established to provide BrainChip with leading insight to the application of Artificial Intelligence across a wide spectrum of use cases including Smart Health. Smart Health is a branch of healthcare where neural network technology, medical and virology research meet to enable new intelligent technologies to deliver the rapid interpretation of clinical tests.

"As BrainChip focuses on the commercialization of its groundbreaking Akida™ AI technology the Company believes strongly that Smart Health is a market of great importance with regard to improving the human condition and providing best-in-class technologies to support the worldwide need for advanced healthcare", said Louis DiNardo, BrainChip President and CEO.

Prof. Barry Marshall added, "BrainChip's technology is exciting and I am delighted to join the company's Scientific Advisory Board and work with Adam Osseiran and Simon Thorpe as well as with Peter van der Made and the BrainChip executive team to bring to fruition the most advanced healthcare solutions."

Prof. Barry Marshall was born in Kalgoorlie, Australia, but spent his childhood from the age of eight in Perth, where he also studied to become a doctor. It was during his employment at the Royal Perth Hospital that he carried out the work with colleague Robin Warren that led to his receiving the Nobel Prize. Prof. Barry Marshall has continued his affiliation with the hospital and university in

For personal use only

Perth, and is also connected to U.S. universities, including the University of Virginia in Charlottesville.

Peptic (stomach and duodenal) ulcers are a common illness, but their cause was thought to be “stress” related until the Perth duo discovered that the most common cause was a bacterial infection. After Robin Warren saw curved bacteria and inflammation in stomach tissue, he collaborated with his young colleague Barry Marshall, who then cultivated the previously unknown bacteria *Helicobacter pylori* (HP). The pair then proved that ulcers could be permanently cured if HP were eradicated and Marshall invented the widely used urea breath test for diagnosis of the bacterium. Cure of peptic ulcer disease is now routinely achieved by treatment with antibiotics. The HP bacterium is also the major cause of stomach cancer, one of the top 3 fatal cancers worldwide, so its global eradication is a continuing health imperative for Professor Marshall.

This announcement is authorised for release by the BRN Board of Directors.

About Brainchip Holdings Ltd (ASX: BRN)

BrainChip is a global technology company that is producing a groundbreaking neuromorphic processor that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. The chip is high performance, small, ultra-low power and enables a wide array of edge capabilities that include on-chip training, learning and inference. The event-based neural network processor is inspired by the spiking nature of the human brain and is implemented in an industry standard digital process. By mimicking brain processing BrainChip has pioneered a processing architecture, called Akida™, which is both scalable and flexible to address the requirements in edge devices. At the edge, sensor inputs are analyzed at the point of acquisition rather than through transmission via the cloud to a data center. Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications. The reduction in system latency provides faster response and a more power efficient system that can reduce the large carbon footprint of data centers.

Additional information is available at <https://www.brainchipinc.com>

Follow BrainChip on Twitter: https://www.twitter.com/BrainChip_inc

Follow BrainChip on LinkedIn: <https://www.linkedin.com/company/7792006>

Company contact:

Louis DiNardo

ldinardo@brainchip.com

+1 (415) 699-9163

BrainChip Holdings Ltd

ACN 151 159 812

Level 12 225 George St Sydney NSW 2000

T: +61 2 9290 9606 | F: +61 2 9297 0664 | W: www.brainchipinc.com